Articles related to LUNG CANCER

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.

The study underscores the potential of osimertinib-chemotherapy combination as a first-line treatment in EGFR-mutated advanced NSCLC, demonstrating a significant improvement in progression-free survival and response rate compared to osimertinib monotherapy.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.